Manufacture and Commercialisation of Stem Cell and Gene Therapies

Overview

This one-year, full-time Manufacture and Commercialisation of Stem Cell and Gene Therapies programme from University College London will involve a combination of both biological and lab-based bioprocessing studies in conjunction with core research-based educational content covering a range of novel therapeutic modalities and the translation of these advanced therapies from the laboratory to the market.

Through close industry partner involvement in the development and delivery of this programme, you will be introduced to real-life case studies of novel therapeutic manufacture. In addition to being taught by UCL academics who will draw upon extensive industrial research collaborations, you will receive lectures from industry experts and guest speakers to provide you with the industrial relevance and the wider commercial context. You will, therefore, benefit greatly from the academic expertise and real-world commercial and clinical insights which will be brought together through this holistic educational approach.

Employability

The rapid developments in the stem cell and gene therapy fields have created skills shortage in this high-value manufacturing sector. Graduates from our undergraduate with a focus on advanced therapies have secured positions at leading national and international companies, ranging from SMEs to large companies including, but not limited to, Autolus, Meira GTx, GSK, Orchard Therapeutics, Novartis, ReNeuron, Sartorius and the Cell and Gene Therapy Catapult.